Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 4/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28399968 | 0.80 | ALB (0.36) | EP300ADORA2B | |
| SCHEMBL11718699 | 0.79 | EP300 (0.43) | EP300KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL27707200 | 0.77 | EP300 (0.42) | EP300ADORA3 | |
| SCHEMBL21546149 | 0.76 | EP300 (0.44) | EP300ADORA2BKDM4EALDH1A1 | |
| SCHEMBL28397945 | 0.75 | EP300 (0.44) | EP300KMT2A | |
| SCHEMBL19711602 | 0.75 | EP300 (0.40) | EP300ADORA3 | |
| SCHEMBL8769047 | 0.73 | ALDH1A1 (0.44) | EP300ADORA2BKDM4EALDH1A1KMT2A | |
| SCHEMBL27299849 | 0.72 | EP300 (0.39) | EP300MEN1ALDH1A1KMT2A | |
| SCHEMBL17041803 | 0.70 | EP300 (0.33) | EP300KDM4EALDH1A1 | |
| SCHEMBL20182182 | 0.70 | DYRK1A (0.32) | ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106883217-B | Nucleoside base hydroxamic acid derivative compound and preparation method and application thereof | 清华大学深圳研究生院 | 2020-05-22 | — | — | CN | disclosed |